Co-Diagnostics, Inc. to Host Booth at AACC Held July 24-28 in Chicago
07/20/2022 - 09:30 AM
The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT .
SALT LAKE CITY July 20, 2022 (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth to showcase its existing and upcoming suite of diagnostics products and technology applications at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, held July 24-28 at the McCormick Place Convention Center in Chicago, IL , in addition to providing an update for its worldwide network of customers and distributors.
Current and potential Co-Dx™ distributors, customers, and partners are invited to join the Company in room S103A at 11:00 AM CT for the Co-Dx global customer and distributor update. Over the past few years, Co-Dx has established a broad and growing distribution network that has sold over 34,000,000 PCR tests in over 50 countries.
On Tuesday at 2:00 pm CT , Company CEO Dwight Egan will also be conducting a presentation at the Company's booth on the Co-Dx PCR Home testing platform and introducing Dr. Kirk Ririe and Dr. Carl Wittwer , pioneers of rapid and real-time PCR, key personnel in the platform's development, and respectively president of the Company's wholly owned subsidiary and Chairman of the Company's Scientific Advisory Board.
Co-Diagnostics invites all interested parties to booth #2878, as well as to the Company's kiosk displaying our forthcoming Co-Dx PCR Home testing platform in the Disruptive Technologies Pavilion following Co-Dx being named a semifinalist in the 2022 AACC Disruptive Technology Award Competition.
To learn more about the conference, including registration and exhibitor details, please visit https://meeting.aacc.org .
The Co-Dx PCR Home testing platform device is subject to FDA review and is not available for sale.
About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-aacc-held-july-24-28-in-chicago-301589931.html
SOURCE Co-Diagnostics
CODX Rankings
#5113 Ranked by Stock Gains
CODX Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Salt Lake City
About CODX
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
